About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 175 entries.

Entries by Haley Chartres

Botanix Releases Quarterly Reports

October 19, 2025 in , , , /by

The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million. Click to view the Reports.

Botanix featured at global investor conference

September 8, 2025 in , , , /by

Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences […]

Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea

September 4, 2025 in , , , /by

Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd. Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive […]

Botanix Releases Annual Report

August 31, 2025 in , , , /by

The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability. View Report.

Dr Patricia Walker Joins Botanix Board

August 25, 2025 in , , , /by

Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix. […]

Botanix investor presentation at Canaccord Genuity event

August 12, 2025 in , , , , /by

Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event. […]

Botanix Releases Quarterly Reports

July 27, 2025 in , , /by

The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is […]